Tocotrienols

Evidence Fact Sheet

Educational reference page covering the unsaturated branch of the vitamin E family — what tocotrienols are, how they differ structurally and mechanistically from the more familiar tocopherols, which plant source (annatto vs palm vs rice bran) actually matters for the dose on the label, what the human-trial record supports for lipid, liver, bone, neurovascular, and anti-inflammatory use, and the α-tocopherol "interference" caveat that quietly undermines half of all real-world tocotrienol regimens. This sub-page sits inside the vitamin E cluster hub alongside the sibling tocopherols sub-page. Not medical advice.

Last reviewed 2026-05-24 · How we assess evidence →

§1 · Quick Summary (60-second read)

Tocotrienols are the four "unsaturated" vitamin E isomers (α-T3, β-T3, γ-T3, δ-T3) — chemically related to the four tocopherols you already know, but with a different mechanism profile, a much shorter plasma half-life, and a small-but-distinctive randomized-trial record in blood lipids, fatty liver, postmenopausal bone health, white-matter brain changes, and systemic inflammation.

Three things to know before you buy:

The plant source on the label decides whether the dose works. Annatto-derived tocotrienol contains ~100% tocotrienol and 0% α-tocopherol and is the form used in most of the strongest modern trials. Palm-derived tocotrienol-rich fraction (palm TRF) contains ~25% α-tocopherol natively, which competes with the tocotrienol for the same transport protein and accelerates its clearance — meaning the same milligram dose can deliver substantially less tocotrienol to your tissues. Rice-bran-derived concentrate is similar to palm but with a lower tocotrienol fraction. See §3.
If you are taking a multivitamin or a "vitamin E" softgel, your tocotrienol is probably being undercut. Most multivitamins and standalone vitamin E products supply 15–30 mg of α-tocopherol — exactly the dose range that meaningfully interferes with tocotrienol absorption and retention. The cleanest fix is an annatto-derived (α-tocopherol-free) tocotrienol, or to separate the two products by at least six hours. See §4.
The evidence base is real, but it is newer and smaller than the tocopherol record. Modern systematic reviews (Rafique 2024) explicitly note "lack of conclusive evidence" for head-to-head superiority of tocotrienol over tocopherol in cardiovascular patients. Tocotrienol trials show good signals on intermediate biomarkers (LDL, fatty-liver indices, bone-resorption markers, CRP, MRI white-matter lesion progression) — they do not yet support hard-outcome claims like "prevents heart attack" or "prevents fracture." See §7.

Bottom line: If you want a vitamin E sufficient to meet the RDA, an α-tocopherol-containing diet and multivitamin already cover that. If you want the distinct mechanistic profile of tocotrienol (HMG-CoA-reductase degradation, NF-κB suppression, mitochondrial protection) for a specific lipid, hepatic, bone, or anti-inflammatory goal, choose an annatto-derived product, take it with a fat-containing meal, respect the U-shape dose-response described in §6, and read §5 before stacking it with any product also containing α-tocopherol.

§2 · What are tocotrienols, and how do they differ from tocopherols?

Tocotrienols are the four unsaturated vitamin E isomers (α/β/γ/δ-T3) — chemically related to the four tocopherols but with a different mechanism profile, a much shorter plasma half-life (hours, not days), and a smaller-but-distinctive RCT record in blood lipids, fatty liver, postmenopausal bone, white-matter brain changes, and systemic inflammation; the plant source on the label (annatto vs palm vs rice bran) decides whether the dose actually works.

Vitamin E is a family of eight vitamers. The vitamin E hub page §2 introduces the full family: four tocopherols (α, β, γ, δ) plus four tocotrienols (α, β, γ, δ), all sharing a chromanol antioxidant head and a 16-carbon lipid tail. This sub-page is about the four-isomer tocotrienol branch.

§2.1 · The structural difference is one detail with three large consequences

The chromanol head is the same. The tail is different.

Tocopherols carry a saturated phytyl tail (no double bonds).
Tocotrienols carry an unsaturated farnesyl tail with three evenly spaced double bonds.

That one structural detail produces three downstream consequences relevant to a reader trying to decide what to take:

Membrane fluidity and depth of penetration. The unsaturated tail moves more freely through membranes, including the mitochondrial inner membrane and the nuclear envelope. Tocotrienols reach intracellular compartments that tocopherols do not reach as easily.
Faster antioxidant kinetics, but a shorter plasma half-life. Tocotrienols quench peroxyl radicals more rapidly in vitro and accumulate well in adipose tissue, but their plasma half-life is hours, not days — the liver's α-tocopherol transfer protein (α-TTP) preferentially shuttles α-tocopherol back into circulation and lets tocotrienols be cleared. The practical implication is that tocotrienols generally need to be taken daily with a meal to maintain tissue levels, whereas α-tocopherol persists in plasma for weeks.
A genuinely different mechanism set. Tocotrienols — particularly γ-T3 and δ-T3 — drive ubiquitin-proteasome degradation of HMG-CoA reductase (the cholesterol-synthesis rate-limiting enzyme), suppress NF-κB-driven inflammation, and modulate STAT3 and VEGF signaling. None of these is a meaningful effect of α-tocopherol at supplemental doses. See §5.

§2.2 · The activity gradient inside the tocotrienol family: δ > γ >> α/β

Among the four tocotrienol isomers, δ-tocotrienol is consistently the most active — strongest at HMG-CoA-reductase degradation, strongest at NF-κB suppression, strongest at antiangiogenic and antitumor signaling in preclinical work. γ-T3 follows next. α-T3 and β-T3 are substantially weaker.

The mechanistic reason is structural: the fewer methyl groups on the chromanol ring, the more accessible the free hydroxyl group that does the antioxidant and signaling work. This is why annatto-derived material — 90% δ-T3 + 10% γ-T3, with zero α-T3 and zero α-tocopherol — is the formulation used in most of the strongest modern tocotrienol trials, even though palm-derived material is more widely available and less expensive.

§3 · Three plant sources — annatto vs palm vs rice bran

Read the supplement label, then read this section. The single most important purchasing decision for a tocotrienol product is the plant source, because the source determines both the isomer mix and the α-tocopherol contamination.

§3.1 · The three sources at a glance

Source	Total tocotrienol	α-tocopherol	Dominant isomers	Strengths	Concerns
Annatto (Bixa orellana seed)	~100%	~0%	90% δ-T3 + 10% γ-T3	Zero α-tocopherol interference (see §4); highest δ-T3 fraction (most active isomer); used in most modern annatto-arm RCTs; no palm-oil sustainability concern	Single fishery-equivalent supply (one tropical seed source); higher cost per milligram
Palm TRF (Elaeis guineensis mesocarp oil — tocotrienol-rich fraction)	70–75%	20–25%	α-T3 + β-T3 + γ-T3 + δ-T3 + α-toc mixed (γ-T3 dominant)	Full-spectrum isomer mix; deepest historical RCT base (Qureshi, Tomeo, Gopalan); moderate cost	The native α-tocopherol fraction self-interferes (see §4); the palm-oil supply chain carries deforestation and sustainability concerns; isomer ratio is fixed
Rice bran (Oryza sativa bran oil)	30–50%	10–30%	α-T3 + γ-T3 + substantial α-toc	Byproduct-utilization value chain; lowest cost	Lowest tocotrienol concentration; highest α-tocopherol interference per labeled milligram; many "rice bran vitamin E" products on the shelf are mostly α-tocopherol, with only a small tocotrienol fraction

§3.2 · The honest sourcing hierarchy

For a reader who wants the mechanistic profile that tocotrienol-specific trials describe — and who is not chasing a specific historical study protocol — the order is straightforward:

First choice for most readers: annatto-derived tocotrienol concentrate. Zero α-tocopherol means no self-interference; the 90% δ-T3 fraction maps onto the activity gradient; and the body of annatto-arm trials (Shen on bone, Pervez on fatty liver, Magosso on NAFLD) is now substantial.
Second choice for readers replicating a specific historical protocol (Tomeo carotid, Gopalan brain white matter, early Qureshi lipid): palm-derived tocotrienol-rich fraction, recognizing the self-interference penalty.
Third choice (cost-driven general antioxidant maintenance only): rice-bran-derived concentrate, with the understanding that effect sizes from tocotrienol-specific trials should not be assumed to transfer.

§3.3 · A simple sourcing decision tree

You are considering a tocotrienol supplement →
├─ Are you already taking a multivitamin or a "vitamin E" softgel containing α-tocopherol?
│   ├─ Yes → Choose annatto-derived tocotrienol (zero α-tocopherol),
│   │        OR stop the α-tocopherol product,
│   │        OR separate the two by ≥6 hours every day.
│   └─ No →
│       ├─ Your goal is the δ-T3-strongest profile (lipid management,
│       │  NAFLD, postmenopausal bone, anti-inflammatory CRP reduction)
│       │  → Annatto-derived tocotrienol.
│       ├─ Your goal is to replicate a published palm-TRF protocol
│       │  (Tomeo carotid, Gopalan brain white-matter)
│       │  → Palm TRF, taken with a meal.
│       └─ Your goal is general antioxidant maintenance with cost as
│          the dominant constraint → rice-bran-derived concentrate
│          is acceptable but the tocotrienol-specific evidence base
│          may not transfer.
├─ Do you have palm-oil sustainability concerns?
│   ├─ Yes → Avoid palm TRF; choose annatto or rice bran.
│   └─ No → Palm TRF remains an option.

§4 · The α-tocopherol "interference" caveat — the single most important real-world detail

This is the section that distinguishes a useful tocotrienol fact sheet from an uncritical one. It is also the section most often missing from product marketing.

§4.1 · The mechanism, in three sentences

The liver's α-tocopherol transfer protein (α-TTP) has a much higher affinity for α-tocopherol than for any tocotrienol isomer. When plasma α-tocopherol is high, α-TTP preferentially loads α-tocopherol onto outgoing VLDL particles and lets tocotrienols be routed into hepatic catabolism (CYP4F2-mediated ω-hydroxylation and CEHC excretion) instead. Within cells, α-tocopherol also out-competes tocotrienols at the membrane uptake step.

§4.2 · The dose threshold where this stops being theoretical

Published pharmacokinetic work indicates that co-administration of more than ~20 mg/day of α-tocopherol with tocotrienol reduces tocotrienol plasma AUC by approximately 30–60%, in a dose-dependent fashion. Comparative trial work (palm TRF arms versus annatto arms, with otherwise matched designs) shows that the lipid and inflammation effects of palm TRF — which carries ~25% native α-tocopherol — are more variable and on average smaller than annatto arms at equivalent total-tocotrienol milligrams.

§4.3 · Why almost every consumer regimen runs into this

A typical multivitamin contains 15–30 mg of α-tocopherol — right on the threshold. A standalone "vitamin E" softgel commonly contains 67–268 mg (100–400 IU) of α-tocopherol — comfortably above the threshold. A "vitamin E complex" or "mixed tocopherols" product can contain 100+ mg of α-tocopherol. Any of these, taken in the same window as a tocotrienol product that does not specify zero α-tocopherol, will reduce the tocotrienol's effective dose.

§4.4 · The three honest ways to handle this

Use an annatto-derived tocotrienol (~100% tocotrienol, 0% α-tocopherol). This is the cleanest fix and the design used in most of the strongest modern trials.
Drop the α-tocopherol product if you are otherwise meeting the RDA from diet (15 mg α-TE/day is achievable from sunflower seeds, almonds, hazelnuts, peanut butter, spinach, avocado, and vegetable oils).
Separate the two by at least six hours every day — for example, multivitamin at breakfast, tocotrienol at dinner — recognizing this is partial mitigation, not full elimination.

This caveat is the dominant reason tocotrienol trial results are sometimes harder to reproduce in real-world supplement users: the trial used annatto or a controlled palm protocol; the user is also taking a multivitamin.

§5 · How tocotrienols work — four pathways the tocopherols do not share

Four pathways largely absent from tocopherols at supplemental doses: HMG-CoA reductase ubiquitin-proteasome degradation (non-statin lipid pathway; γ-T3/δ-T3 only), NF-κB/IKK suppression (anti-inflammatory; δ-T3 > γ-T3 >> α/β), STAT3/VEGF modulation, and Nrf2 + mitochondrial-inner-membrane antioxidant protection enabled by the unsaturated farnesyl tail — with α-TTP competition meaning high α-tocopherol routes tocotrienol to hepatic catabolism.

The vitamin E hub page §3 covers the general chromanol antioxidant chemistry that the whole vitamin E family shares — chain-terminating peroxyl-radical quenching, vitamin C-mediated regeneration, and Nrf2/ARE activation of endogenous antioxidant enzymes. This sub-page covers the four pathways that are specific to tocotrienols and largely absent from tocopherols at supplemental doses.

§5.1 · HMG-CoA reductase degradation — a non-statin lipid-lowering pathway

γ-Tocotrienol and δ-tocotrienol cause the sterol-sensing domain of HMG-CoA reductase (the rate-limiting enzyme of cholesterol biosynthesis) to change conformation, which recruits the gp78 ubiquitin ligase and routes the enzyme to proteasomal degradation. This is mechanistically distinct from statins, which competitively inhibit the enzyme's active site without degrading the enzyme protein itself. The pathways are complementary, not redundant — but α-tocopherol does not drive this pathway, and at high doses some early literature even reports the opposite effect on enzyme expression. This is the mechanistic basis for the dose-dependent LDL and total-cholesterol reductions observed in Qureshi 2002 (PMID 11882333) and the rationale for studying tocotrienol add-on to statins.

§5.2 · NF-κB suppression — the anti-inflammatory pathway

δ-tocotrienol inhibits IκB kinase (IKK) activity, preventing IκBα phosphorylation and degradation, keeping the NF-κB p65/p50 dimer in the cytoplasm rather than entering the nucleus, and downregulating transcription of TNF-α, IL-6, IL-1β, COX-2, iNOS, and VCAM-1. The potency gradient is δ-T3 > γ-T3 >> α-T3 / β-T3, tracking the activity gradient described in §2.2. The 2021 Khor systematic review and meta-analysis of 19 RCTs (PMID 34297765) found a statistically significant reduction in C-reactive protein following tocotrienol supplementation, consistent with this mechanism.

§5.3 · STAT3 / VEGF modulation — a vascular and proliferation pathway

δ-tocotrienol inhibits JAK2/STAT3 signaling and modulates VEGFR2 downstream PI3K/Akt — pathways involved in angiogenesis and cellular proliferation. The clinical evidence base here is still early (a small Phase II in neoadjuvant breast cancer; preclinical and animal work), and tocotrienol should not be presented as a cancer therapy. This pathway is included for mechanistic completeness, not as a benefit claim.

§5.4 · Nrf2 activation and mitochondrial antioxidant protection

All vitamin E isomers activate Nrf2 to some degree (covered on the hub page), but tocotrienols carry a distinctive advantage at the mitochondrial inner membrane because the unsaturated farnesyl tail penetrates more readily — directly protecting respiratory-chain complexes and reducing mitochondrial reactive oxygen species. α-Tocopherol, with its saturated tail, does not reach this compartment as effectively.

§5.5 · The α-TTP competition that ties this whole page together

Section 4 covers the consumer-facing version of this; mechanistically it means the dose-response relationship for tocotrienols depends strongly on co-existing α-tocopherol concentrations. This is why annatto-arm trials (zero α-tocopherol) produce more consistent effect sizes per milligram of tocotrienol than palm-TRF-arm trials (~25% native α-tocopherol).

§6 · What the human evidence actually shows

The tocotrienol evidence base is real but newer and smaller than the tocopherol record. There are no SELECT- or HOPE- or ATBC-scale long-term hard-outcome trials. What there is, organized by goal:

§6.1 · Blood lipids — the deepest tocotrienol evidence base, with a U-shape

RCT (single dose-ranging trial + narrative SR)

Qureshi 2002 randomized 90 adults with elevated cholesterol to rice-bran-derived tocotrienol concentrate; dose-dependent reduction in total cholesterol (14–17%) and LDL (15–22%), peaking at 100–200 mg/day, reversing above 250 mg/day — the U-shape dose-response.

n=90adults with elevated cholesterol randomized (rice-bran TRF25, 4–8 weeks)
−14–17% / −15–22%total cholesterol / LDL reduction, peaking 100–200 mg/day
>250 mg/daydose above which effect reverses (U-shape)

Qureshi 2002 (Atherosclerosis; PMID 11882333) randomized 90 adults with elevated cholesterol to a multi-dose protocol of rice-bran-derived tocotrienol concentrate (TRF25) over 4–8 weeks. Results: dose-dependent reduction in total cholesterol (14–17%) and LDL (15–22%), peaking at 100–200 mg/day. Above 250 mg/day, the effect reversed — because tocotrienols undergo metabolic conversion to α-tocopherol at higher doses, generating the same self-interference described in §4. This U-shape dose-response is the single most important honest detail in tocotrienol dosing: more is not better.

Rafique 2024 (J Pak Med Assoc; PMID 38948984) is the most recent narrative systematic review on tocotrienol versus tocopherol in atherosclerosis. The honest conclusion: tocotrienol "may be more effective" on mechanistic and intermediate-biomarker grounds, but the authors explicitly note that they could not find data directly comparing tocopherol and tocotrienol efficacy in cardiovascular patients and that there is a "lack of conclusive evidence." This sub-page reports that conclusion as stated.

§6.2 · Carotid atherosclerosis — one long-duration imaging trial

RCT (single long-duration imaging trial, not replicated)

Tomeo 1995 randomized 50 hyperlipidemia + carotid-stenosis patients to palm tocotrienol 160 mg/day + α-tocopherol 64 mg/day vs placebo for 18 months; carotid plaque regression in 7/25 treated vs 0/25 placebo, progression in 2/25 treated vs 10/25 placebo.

n=50hyperlipidemia + carotid-stenosis patients, 18 months
7/25 vs 0/25carotid plaque regression, treated vs placebo
2/25 vs 10/25disease progression, treated vs placebo

Tomeo 1995 (Lipids; PMID 8614310) randomized 50 patients with hyperlipidemia and carotid artery stenosis to palm-derived tocotrienol (160 mg/day) plus α-tocopherol (64 mg/day) versus placebo for 18 months, with carotid duplex ultrasound as the structural endpoint. Results: carotid plaque regression in 7 of 25 treated patients versus 0 of 25 placebo, and disease progression in only 2 of 25 treated versus 10 of 25 placebo. This is one of the few tocotrienol trials with a structural cardiovascular imaging endpoint and a long enough duration to show plaque-level change. It has not been replicated at equivalent scale and imaging quality, and the design pre-dates the annatto-versus-palm sourcing distinction.

§6.3 · Non-alcoholic fatty liver disease — two reasonable-quality RCTs

RCT (two reasonable-quality RCTs + supportive SR)

Two RCTs (Magosso 2013 mixed tocotrienol over 12 months, Pervez 2020 δ-T3 600 mg/day over 24 weeks) showed improvements in liver enzymes, Fatty Liver Index, ultrasound-graded steatosis and inflammatory markers; Chin 2023 SR judges the evidence supportive but moderate quality.

n=87Magosso 2013 mixed tocotrienol 200 mg BID, 12 months
n=71 · 600 mg/d δ-T3Pervez 2020 δ-tocotrienol 300 mg BID, 24 weeks
↓ALT/AST/FLI/steatosis/hs-CRP/MDA/HOMA-IRPervez multi-marker improvement profile

Magosso 2013 (Nutr J; PMID 24373555) randomized 87 adults with elevated cholesterol and ultrasound-confirmed NAFLD to mixed tocotrienol (200 mg twice daily) or placebo for 12 months, with hepatic ultrasound echogenic response as the primary endpoint. The tocotrienol arm achieved significantly greater normalization of ultrasound-graded steatosis than placebo over a year.

Pervez 2020 (Complement Ther Med; PMID 32951743) randomized 71 overweight or obese adults with metabolic syndrome and ultrasound-confirmed NAFLD to δ-tocotrienol 300 mg twice daily (600 mg/day) or placebo for 24 weeks. Results: significant reductions in ALT, AST, Fatty Liver Index, ultrasound-graded steatosis, hs-CRP, MDA, and HOMA-IR. The δ-T3-only design and the multi-marker improvement profile make this one of the cleanest annatto-equivalent NAFLD trials in the literature.

The Chin 2023 systematic review of tocotrienols in NAFLD (PMID 36839192) integrates these alongside earlier work and concludes the evidence is supportive but of moderate quality.

§6.4 · Postmenopausal bone health — the strongest annatto-specific signal

RCT (single 12-week bone-turnover biochemistry trial, not BMD/fracture)

Shen 2018 randomized 87 postmenopausal osteopenic women to 430 or 860 mg/day annatto tocotrienol + 400 IU vitamin D + 500 mg calcium over 12 weeks; significant dose-related reduction in bone-resorption markers (incl. CTX) and oxidative-stress markers — a bone-turnover trial, not a BMD or fracture trial.

n=87postmenopausal osteopenic women, 12 weeks
430 / 860 mg/dayannatto 70% tocotrienol doses (+ vit D + Ca)
↓ CTX + oxidative-stress markersdose-related bone-resorption marker reduction

Shen 2018 (BMC Complement Altern Med; PMID 29954374) is the trial that defines the postmenopausal-bone use case for annatto tocotrienol. The design: 87 postmenopausal osteopenic women, randomized to placebo, 430 mg/day, or 860 mg/day of 70%-pure annatto tocotrienol (90% δ-T3 + 10% γ-T3), all arms also receiving 400 IU/day vitamin D plus 500 mg/day calcium, over 12 weeks. Results: significant dose-related reduction in bone-resorption markers (including CTX) and significant reduction in oxidative-stress markers, with a safety profile equivalent to placebo.

This is not a trial of bone mineral density or fracture endpoints. It is a 12-week mechanistic trial of bone-turnover biochemistry. The honest framing is: tocotrienol shifts the bone-resorption biochemistry in the direction associated with reduced bone loss, in postmenopausal osteopenic women, when combined with adequate vitamin D and calcium. It does not show that tocotrienol prevents osteoporotic fracture — a fracture endpoint trial has not been conducted.

§6.5 · Brain white-matter lesions — one two-year MRI trial

RCT (single 2-year MRI risk-marker trial, not clinical endpoint)

Gopalan 2014 randomized 121 adults (per-protocol 88) with cardiovascular risk + MRI white-matter lesions to mixed tocotrienol 400 mg/day vs placebo for two years; tocotrienol arm showed essentially no progression of white-matter lesion volume while placebo progressed — an imaging risk marker, not a stroke/dementia endpoint.

n=121 (PP 88)adults 35+ with CV risk + MRI white-matter lesions, 2 years
400 mg/daymixed tocotrienol (200 mg twice daily)
no progression vs significant progressionWML volume, tocotrienol vs placebo

Gopalan 2014 (Stroke; PMID 24699052) randomized 121 adults aged 35+ with cardiovascular risk and MRI-confirmed white-matter lesions to mixed tocotrienol (200 mg twice daily) or placebo for two years, with MRI white-matter lesion volume as the primary endpoint. Per-protocol analysis (n=88): the tocotrienol arm showed essentially no progression of white-matter lesion volume, while the placebo arm showed significant progression.

White-matter lesions are a risk marker for stroke and vascular dementia, not a clinical endpoint. The honest framing of this trial is: tocotrienol slowed MRI-detected white-matter lesion progression in adults at cardiovascular risk over two years. It is not a trial showing that tocotrienol prevents stroke or dementia, and it should not be cited that way.

§6.6 · Systemic inflammation — a meta-analysis-level signal

Meta-analysis (19 RCT SR/MA)

Khor 2021 systematically reviewed and meta-analyzed 19 randomized trials of tocotrienol supplementation (13 in the quantitative MA); pooled effect was a statistically significant reduction in CRP, with several oxidative-stress markers also improved amid substantial heterogeneity.

19 RCT (13 in MA)tocotrienol supplementation trials reviewed
statistically significant ↓ CRPpooled effect on C-reactive protein
MDA/SOD/GPx improvedoxidative-stress markers (substantial heterogeneity)

Khor 2021 (PLOS ONE; PMID 34297765) systematically reviewed and meta-analyzed 19 randomized trials of tocotrienol supplementation (13 in the quantitative meta-analysis), with C-reactive protein as the most consistently reported inflammatory outcome. The pooled effect was a statistically significant reduction in CRP. Several oxidative-stress markers (MDA, SOD, GPx) also improved, with substantial heterogeneity across studies.

The honest framing: a 2021 meta-analysis of 19 RCTs reports a statistically significant reduction in CRP following tocotrienol supplementation, supporting a role in modulating systemic inflammation — without claiming tocotrienol treats any specific inflammatory disease.

§7 · Dose by goal

Context-dependent: 50–125 mg/d general; 100–200 mg/d lipid (Qureshi U-shape peak, >250 mg/d reverses); 200–300 mg/d mixed or 600 mg/d δ-T3 NAFLD; 430–860 mg/d annatto for postmenopausal bone-turnover (+ vit D + Ca); always with a fat-containing meal (≥10 g fat); avoid stacking with >20 mg/d α-tocopherol or separate by ≥6 h / use annatto-only.

Use case	Tocotrienol daily dose	Preferred source	Time course	Source basis
General antioxidant maintenance	50–125 mg	Annatto-derived	Daily, with meal	NIH-ODS background; tocotrienol-specific evidence base
Lipid management (elevated TC / LDL)	100–200 mg (U-shape peak; >250 mg/day reduces effect)	Annatto-derived δ-T3	4–8 weeks to onset	Qureshi 2002 PMID 11882333
Carotid plaque protocol replication	160–250 mg	Palm TRF (the protocol used in the trial)	6–18 months	Tomeo 1995 PMID 8614310
White-matter lesion protocol replication	200 mg twice daily	Palm mixed tocotrienol (Gopalan protocol)	6–24 months	Gopalan 2014 PMID 24699052
NAFLD	200–300 mg/day mixed tocotrienol, or 600 mg/day δ-T3	Mixed or annatto δ-T3	12–24 weeks to 12 months	Magosso 2013 PMID 24373555; Pervez 2020 PMID 32951743
Postmenopausal bone-turnover protocol	430–860 mg/day annatto 70% tocotrienol plus 400 IU vitamin D plus 500 mg calcium	Annatto-derived	12 weeks	Shen 2018 PMID 29954374
Anti-inflammatory / CRP-lowering	100–400 mg/day	Annatto-derived δ-T3	8–12 weeks	Khor 2021 SR PMID 34297765
Take with food or empty stomach?	Always with a fat-containing meal (≥10 g fat) — chylomicron-dependent absorption; fasting reduces plasma AUC ~30–50%+	Any source	—	Lipid pharmacology
Co-supplementation cap	Avoid stacking with high-dose α-tocopherol (>20 mg/day); separate by ≥6 hours or use annatto-only	—	—	§4 above
Human safety ceiling demonstrated in trials	600–860 mg/day for 12–24 weeks with placebo-equivalent safety	—	—	Shen 2018 PMID 29954374; Pervez 2020 PMID 32951743
Rodent NOAEL (90-day)	≥1000 mg/kg body weight/day	—	—	EFSA-cited toxicology

Three dosing honesty points specific to tocotrienol:

The U-shape is real. 100–200 mg/day is the lipid-effect peak in Qureshi 2002; above ~250 mg/day, tocotrienol begins converting to α-tocopherol fast enough to self-interfere. More is not better.
A fat-containing meal is non-negotiable. Tocotrienols are fat-soluble and depend on chylomicron transport. Fasting administration loses a substantial fraction of the dose to first-pass effects. Take with breakfast or dinner that contains visible fat.
EFSA's 300 mg/day Tolerable Upper Intake Level for vitamin E is set on α-tocopherol and explicitly does not extrapolate directly to tocotrienols. The human safety record for tocotrienol-only intake up to 600–860 mg/day for several months in supervised trials is the relevant reference for the upper end of supplemental use.

§8 · Safety and drug interactions

§8.1 · The general safety profile

Across 40+ human randomized trials, tocotrienol has been well-tolerated. Common side effects are uncommon and mild (occasional gastrointestinal complaints at rates similar to placebo). No serious adverse events have been attributed to tocotrienol in the published trial record at doses up to 860 mg/day for 12 weeks (Shen 2018) and 600 mg/day for 24 weeks (Pervez 2020).

§8.2 · Drug interactions to discuss with a prescribing clinician

Drug class	Interaction summary	Practical handling
Warfarin and other anticoagulants	Theoretical bleeding risk (a general vitamin E family caution; tocotrienol-specific evidence is limited). Higher-dose tocotrienol (≥300 mg/day) combined with anticoagulation warrants medical supervision.	If you take an anticoagulant and want to use tocotrienol, inform your prescriber and arrange INR / bleeding monitoring.
Statins (HMG-CoA reductase inhibitors)	Mechanistically complementary, not antagonistic — statins competitively inhibit the enzyme, tocotrienol degrades the enzyme protein. Theoretically additive on lipid endpoints.	Patients on statins with persistent LDL elevation may discuss tocotrienol add-on with their prescriber; not a self-prescribed combination.
Chemotherapy	Interaction data are limited; tocotrienol is not appropriate for self-initiation by patients undergoing cancer treatment.	Use only under oncology supervision.
High-dose α-tocopherol supplements or multivitamins (>20 mg α-tocopherol/day)	Reduces tocotrienol bioavailability via α-TTP competition (see §4).	Choose an annatto-derived tocotrienol (zero α-tocopherol), or separate the two products by ≥6 hours.

§8.3 · Pregnancy, breastfeeding, and pediatrics

No dedicated safety data exist for tocotrienol in pregnancy, breastfeeding, or pediatric populations. The honest position is: do not use tocotrienol supplements during pregnancy or while breastfeeding without prescriber guidance, and tocotrienol is not recommended for children at supplemental doses.

§8.4 · An important clarification — tocotrienol is not cod liver oil

Some readers arrive at this page after reading about cod liver oil and its vitamin A teratogenicity (covered in the fish oil sub-page §6.3). Tocotrienol products — annatto, palm, and rice bran alike — do not contain vitamin A. The vitamin A pregnancy concern that applies to cod liver oil does not apply to tocotrienol. The two products are not related and should not be confused.

§9 · Tocotrienols vs tocopherols — when to pick which

The full eight-isomer vitamin E family discussion lives on the vitamin E hub page. The head-to-head comparison with tocopherols specifically lives on the tocopherols sub-page. This section is the quick decision matrix.

Dimension	Tocopherols (sub-page)	Tocotrienols (this page)	How to choose
RDA / regulatory calculus	α-tocopherol is the FDA RDA 15 mg α-TE/day reference vitamer	Not included in vitamin E RDA calculations	If your goal is to meet the vitamin E RDA, that is a tocopherol question.
Large hard-outcome trials	SELECT, HOPE, ATBC — predominantly null or unfavorable for high-dose α-tocopherol long-term primary prevention	Absent at this scale	Neither family supports universal high-dose long-term use.
HMG-CoA reductase degradation pathway	None	γ-T3 and δ-T3 only — mechanistically complementary to statins	Lipid management with a non-statin mechanism: tocotrienol.
NF-κB suppression	Weak at supplemental doses	δ-T3 strong, γ-T3 moderate	Anti-inflammatory mechanism: tocotrienol.
Mitochondrial membrane penetration	Limited	Strong (unsaturated tail)	Mitochondrial antioxidant goal: tocotrienol.
Plasma persistence	α-tocopherol persists for days (α-TTP-mediated retention)	Hours; requires daily dosing with meal	Steady-state vitamin E plasma maintenance: α-tocopherol; targeted mechanistic intervention: tocotrienol with meal.
Cross-supplementation interference	Does not interfere with tocotrienol	High-dose α-tocopherol (>20 mg/day) interferes with tocotrienol (see §4)	If both are used, choose an annatto-derived tocotrienol or separate by ≥6 hours.

§9.1 · A simple user decision tree

You are considering vitamin E supplementation →
├─ Goal: meet the vitamin E RDA / general antioxidant background?
│   → Diet plus, optionally, a multivitamin with ~15 mg α-tocopherol.
│     Tocotrienol is not required.
├─ Goal: lipid management, NAFLD, postmenopausal bone-turnover,
│         CRP-lowering, mitochondrial antioxidant focus?
│   → Annatto-derived tocotrienol (zero α-tocopherol), with a meal,
│     at the dose for your specific goal in §7.
├─ Goal: brain white-matter / cardiovascular-risk neurovascular protection?
│   → Mixed tocotrienol (palm Gopalan protocol) or annatto, 200–400 mg/day,
│     long-term, with a meal.
└─ You take a multivitamin or a "vitamin E" softgel containing α-tocopherol?
    → Choose annatto-derived tocotrienol (no interference),
      or separate the two products by ≥6 hours every day,
      or stop the α-tocopherol product if your diet already meets the RDA.

Cluster Sibling Sub-pages

This sub-page sits inside the vitamin E cluster hub. The sibling sub-page covers the saturated branch of the family:

Tocopherols (α / β / γ / δ-Tocopherol) — Saturated branch of vitamin E · α-tocopherol is the FDA RDA 15 mg α-TE/day reference vitamer · SELECT / HOPE / ATBC long-term hard-outcome record · plasma persistence days, not hours

§11 · References

All tocotrienol-specific PMIDs verified against PubMed (2026-05-24). Effect sizes are reported as published. For SELECT (α-tocopherol high-dose prostate cancer signal), HOPE / HOPE-TOO (α-tocopherol cardiovascular outcomes), ATBC (α-tocopherol smoker primary prevention), the full RRR-vs-all-rac stereochemistry discussion, and the FDA RDA / EFSA UL regulatory framework, see the vitamin E cluster hub page §4 and §10.

Tocotrienol-specific PMIDs cited on this page

PMID 11882333 · Qureshi AA, Sami SA, Salser WA, Khan FA (2002) · "Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans" · Atherosclerosis 161(1):199–207 · n=90 · rice-bran TRF25 · TC -14–17%, LDL -15–22% peaking 100-200 mg/d · U-shape reversal above ~250 mg/d
PMID 8614310 · Tomeo AC, Geller M, Watkins TR, Gapor A, Bierenbaum ML (1995) · "Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis" · Lipids 30(12):1179–83 · n=50 · palm 160 mg/d + α-toc 64 mg/d · 18 months · carotid plaque regression 7/25 vs 0/25; progression 2/25 vs 10/25
PMID 24699052 · Gopalan Y, Shuaib IL, Magosso E et al. (2014) · "Clinical investigation of the protective effects of palm vitamin E tocotrienols on brain white matter" · Stroke 45(5):1422–8 · n=121 (per-protocol 88) · mixed tocotrienol 400 mg/d · 2 years · MRI white-matter lesion progression slowed
PMID 24373555 · Magosso E, Ansari MA, Gopalan Y et al. (2013) · "Tocotrienols for normalisation of hepatic echogenic response in NAFLD: a randomised placebo-controlled clinical trial" · Nutr J 12:166 · n=87 · mixed tocotrienol 400 mg/d · 12 months · significant normalization of ultrasound-graded steatosis
PMID 32951743 · Pervez MA, Khan DA, Slehria AUR, Ijaz A (2020) · "Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with non-alcoholic fatty liver disease" · Complement Ther Med 52:102494 · n=71 · δ-T3 600 mg/d · 24 weeks · ↓ALT/AST/FLI/steatosis/hs-CRP/MDA/HOMA-IR
PMID 29954374 · Shen CL, Mo H, Yang S et al. (2018) · "A 12-week evaluation of annatto tocotrienol supplementation for postmenopausal women: safety, bone turnover, oxidative-stress markers" · BMC Complement Altern Med 18(1):198 · n=87 postmenopausal osteopenic women · 430 or 860 mg/d annatto 70% tocotrienol + vit D + Ca · 12 weeks · dose-related reduction in bone-resorption markers (CTX) + oxidative-stress markers
PMID 34297765 · Khor BH, Tiong HC, Tan SC et al. (2021) · "Effects of tocotrienol supplementation on markers of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials" · PLOS ONE 16(7):e0255205 · 19 RCTs (13 in MA) · statistically significant CRP reduction; MDA/SOD/GPx improved with heterogeneity

Supporting systematic reviews

PMID 38948984 · Rafique S et al. (2024) · "Comparative effectiveness of tocotrienols versus tocopherols in atherosclerosis: a systematic review" · J Pak Med Assoc 74(6) · honest "lack of conclusive evidence" conclusion for head-to-head efficacy comparison
PMID 36839192 · Chin (2023) · Systematic review of tocotrienols in NAFLD · integrates Magosso 2013 + Pervez 2020 + earlier work · supportive but moderate quality

Hub-page cross-link (vitamin E family-wide trials)

For SELECT (α-tocopherol high-dose prostate cancer signal), HOPE / HOPE-TOO (α-tocopherol cardiovascular outcomes), ATBC (α-tocopherol smoker primary prevention), the full RRR-vs-all-rac stereochemistry discussion, and the FDA RDA / EFSA UL regulatory framework, see the vitamin E cluster hub page §4 and §10.

Regulatory and Public-Health References (not counted in PMID total)

EFSA · Tolerable Upper Intake Level for vitamin E 300 mg/day is set on α-tocopherol and explicitly does not extrapolate directly to tocotrienols
NIH-ODS · Background on vitamin E vitamers, dietary reference intakes (α-TE basis), and food-source data
FDA RDA · 15 mg α-TE/day reference vitamer is α-tocopherol (tocotrienols are not included in RDA calculations)

Cross-links

Parent hub: Vitamin E (eight-isomer family) cluster page →
Sibling sub-page: Tocopherols (α / β / γ / δ-tocopherol) →
Related antioxidant sub-pages: Astaxanthin → · Alpha-Lipoic Acid → · NAC →
Anti-confusion cross-link: Fish oil sub-page §6.3 (cod liver oil and vitamin A) → · tocotrienol is not cod liver oil and contains no vitamin A

Educational Disclaimer

This page is educational content and not medical advice. It does not diagnose, treat, cure, or prevent any disease. Tocotrienol is not a substitute for prescribed lipid-lowering, anticoagulant, or any other medication. Consult a qualified healthcare provider for individual recommendations, especially if you are pregnant, breastfeeding, on prescription medication, or managing a chronic condition. Brand and product names are not endorsed; the criteria described (annatto vs palm vs rice bran sourcing, zero α-tocopherol for clean pharmacokinetics, third-party-tested manufacturing, and isomer-disclosure transparency) are evidence-based generic standards that any compliant product can meet.

§10 · Frequently Asked Questions

The questions below are the most-searched questions on tocotrienols across general web search and AI assistants. Answers reflect the evidence cited throughout this page and are intentionally concise; deeper detail lives in the relevant sections above.

1. What are tocotrienols, and how are they different from "regular" vitamin E?

Vitamin E is a family of eight related molecules — four tocopherols and four tocotrienols. "Regular vitamin E" in most products means α-tocopherol. Tocotrienols carry an unsaturated tail, penetrate mitochondrial and nuclear membranes more readily, drive HMG-CoA reductase degradation, suppress NF-κB-mediated inflammation, and have a shorter plasma half-life. They are not interchangeable with α-tocopherol — different mechanism profile, different evidence base, different dosing window. See §2.

2. Which source of tocotrienol is best — annatto, palm, or rice bran?

Annatto is the best choice for most readers because it contains ~100% tocotrienol and zero α-tocopherol (eliminating the self-interference problem described in §4), with 90% of its content as the most active δ-T3 isomer. Palm-derived tocotrienol-rich fraction is acceptable when replicating a specific historical trial protocol (Tomeo carotid, Gopalan brain) and carries ~25% native α-tocopherol. Rice-bran-derived concentrate is the lowest-cost option but also the lowest tocotrienol fraction with the highest α-tocopherol interference. See §3.

3. Can I take tocotrienol together with my multivitamin?

Usually not in the same window — most multivitamins supply 15–30 mg of α-tocopherol, which is at or above the threshold that meaningfully reduces tocotrienol absorption and retention. Choose an annatto-derived tocotrienol (zero α-tocopherol, no interference), or separate the multivitamin and the tocotrienol by at least six hours every day, or — if your diet already meets the vitamin E RDA — discontinue the standalone α-tocopherol product. See §4.

4. Do tocotrienols really lower cholesterol?

The honest answer is dose-specific. Qureshi 2002 (PMID 11882333) showed dose-dependent reductions of approximately 14–17% in total cholesterol and 15–22% in LDL at 100–200 mg/day in adults with elevated cholesterol. Above ~250 mg/day, the effect reverses (the U-shape described in §6.1). Tocotrienol works through a different pathway than statins (enzyme degradation, not active-site inhibition) and is not a replacement for statin therapy when statins are indicated.

5. Can tocotrienols help with fatty liver / NAFLD?

Two reasonable-quality randomized trials suggest yes for intermediate biomarkers — Magosso 2013 (PMID 24373555) with mixed tocotrienol over 12 months and Pervez 2020 (PMID 32951743) with δ-tocotrienol 600 mg/day over 24 weeks. Both showed improvements in liver enzymes (ALT, AST), Fatty Liver Index, ultrasound-graded steatosis, and inflammatory markers. This evidence supports the use of tocotrienol as an adjunct in NAFLD management strategies; it does not establish tocotrienol as a cure for fatty liver disease, and a hepatologist should be involved in any clinical NAFLD plan.

6. Are tocotrienols good for bone health in menopause?

Shen 2018 (PMID 29954374) randomized 87 postmenopausal osteopenic women to 430 or 860 mg/day annatto tocotrienol plus 400 IU vitamin D and 500 mg calcium over 12 weeks, and found dose-related reduction in bone-resorption markers and oxidative-stress markers. This is a bone-turnover biochemistry trial, not a bone-mineral-density or fracture trial. The evidence supports annatto tocotrienol — combined with adequate vitamin D and calcium — as a postmenopausal bone-turnover intervention. It does not yet support a fracture-prevention claim.

7. Can tocotrienols help prevent stroke or dementia?

Gopalan 2014 (PMID 24699052) showed in a two-year RCT of 121 adults with cardiovascular risk and MRI-detected white-matter lesions that mixed tocotrienol 400 mg/day slowed white-matter lesion progression. White-matter lesions are a risk marker for stroke and vascular dementia, not a clinical endpoint. The honest statement is that tocotrienol slowed an imaging risk marker in this trial; no tocotrienol trial has shown a reduction in stroke or dementia incidence as a clinical endpoint.

8. Should I take tocotrienol with food or on an empty stomach?

Always with a fat-containing meal (≥10 g of fat). Tocotrienols are fat-soluble and depend on chylomicron transport for intestinal absorption; fasting administration loses an estimated 30–50%+ of the dose. Breakfast or dinner that includes visible fat (eggs, nuts, avocado, oil, dairy) is the practical guideline.

9. Can I take tocotrienol if I am on warfarin or another blood thinner?

Higher-dose tocotrienol (≥300 mg/day) combined with anticoagulation warrants medical supervision and INR / bleeding monitoring. This is the same general caution that applies to the rest of the vitamin E family. Inform your prescribing physician before adding tocotrienol if you are taking warfarin, a DOAC, or any antiplatelet agent.

10. Is tocotrienol the same as the vitamin A in cod liver oil?

No. Tocotrienol is vitamin E (the unsaturated branch). Cod liver oil contains vitamin A and vitamin D (and EPA + DHA from the fish), with the vitamin A content carrying a pregnancy-teratogenicity concern at high doses. Tocotrienol products contain no vitamin A. The two are unrelated and should not be confused — see fish oil sub-page §6.3 for the cod liver oil discussion.

← Back to Vitamin E cluster hub · All Ingredients